The AMR burden in Japan.
Antimicrobial resistance (AMR) is approaching a critical tipping point. Already associated with 4.7 million deaths a year, the toll is expected to increase by more than 70% by 2050.
In 2021, an estimated 17,400 deaths in Japan were caused by drug-resistant infections, and around 83,900 deaths were associated with AMR overall. Older people, particularly those aged 70 and above, are disproportionately affected, with especially high mortality linked to bloodstream and urinary tract infections.
GARDP’s work in Japan.
Japan is a key partner and long-term supporter of GARDP. Not only has the Government of Japan backed GARDP since 2020, but the government has also demonstrated global leadership on AMR through initiatives such as the G7 and G20. A critical pillar of GARDP’s work in Japan is through its collaboration with leading Japanese pharmaceutical companies and academic institutions on drug discovery, compound screening, and clinical development.
Japan’s vital collaboration with GARDP not only strengthens the country’s local capacity and readiness to address AMR, but also ensures that Japan remains at the forefront of global health innovation.
Today, GARDP has a physical presence in Japan, with an office in Tokyo shared with DNDi, and its collaboration with Japan continues to be strengthened, covering almost every aspect of the work we do, from our integrated R&D to access approach, to our innovative use of licensing agreements.
Our partners
Press releases
Landmark clinical trial to transform treatment options for newborns with sepsis expands to Asia
Read more
DNDi, GARDP, and MMV join forces to accelerate drug development for patients in greatest need
Read more
The European Commission invests in CARB-X and GARDP to ramp up global response to antimicrobial resistance
Read more
Resources
GARDP Strategic Plan 2024–2028
GARDP’s strategy through 2028 aims to demonstrate that its unique research and development partnership model can help address the public health crisis of antimicrobial resistance by delivering appropriate treatments to the people who need them most.
This Japanese edition includes a special section, “GARDP and Japan’s Special Relationship” (pages 12–15).